We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01638832
Recruitment Status : Unknown
Verified June 2012 by Johann Wolfgang Goethe University Hospital.
Recruitment status was:  Recruiting
First Posted : July 12, 2012
Last Update Posted : July 12, 2012
Sponsor:
Information provided by:
Johann Wolfgang Goethe University Hospital

July 5, 2012
July 12, 2012
July 12, 2012
June 2012
September 2013   (Final data collection date for primary outcome measure)
Liver fibrosis scores I-IV (METAVIR)

METAVIR fibrosis scores:

I = mild fibrosis II = significant fibrosis III = advanced fibrosis IV = cirrhosis

Same as current
No Changes Posted
Steatosis fibrosis scores I-III

Steatosis scores:

0 = <5% I = 5-33% II = 33-66% III = >66%

Same as current
Not Provided
Not Provided
 
Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease
Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease

This study will evaluate the association of non-alcoholic fatty liver disease and coronary artery disease. All patients presenting for coronary angiogram will receive the following examination:

  • Transient Elastography and Controlled Attenuation Parameter using the FibroScan
  • blood examination including biochemical markers The results of non-invasive liver steatosis and fibrosis measurement are compared with the results of coronary angiogram concerning the presence or absence of coronary artery disease.
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Nonalcoholic Steatohepatitis (NASH)
  • Device: Transient Elastography (FibroScan), Echosens, Paris, France
  • Device: Controlled Attenuation Parameter (CAP), Echosens, Paris, France
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
572
December 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female, 18 years and older
  • Written consent
  • Coronary angiogram planned

Exclusion Criteria:

  • Patients with mental diseases
  • Pregnancy or lactation
  • Ascites
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01638832
JWGUHMED1-005
No
Not Provided
Not Provided
Not Provided
Johann Wolfgang Goethe University Hospital
Not Provided
Principal Investigator: Mireen Friedrich-Rust, MD Klinikum der J. W. Goethe-Universität Frankfurt am Main
Johann Wolfgang Goethe University Hospital
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP